Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 7 years, with Q3 2025 value amounting to $56.5 million.

  • Ascendis Pharma A's Other Non-Current Liabilities rose 2170.65% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 2170.65%. This contributed to the annual value of $73.6 million for FY2024, which is 6601.93% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Other Non-Current Liabilities stood at $56.5 million, which was up 2170.65% from $45.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Other Non-Current Liabilities registered a high of $72.6 million during Q4 2024, and its lowest value of $14.1 million during Q1 2022.
  • For the 5-year period, Ascendis Pharma A's Other Non-Current Liabilities averaged around $35.4 million, with its median value being $33.5 million (2021).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 474.99% in 2022, then skyrocketed by 6391.13% in 2024.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Other Non-Current Liabilities stood at $34.3 million in 2021, then dropped by 4.75% to $32.6 million in 2022, then skyrocketed by 35.75% to $44.3 million in 2023, then soared by 63.91% to $72.6 million in 2024, then fell by 22.25% to $56.5 million in 2025.
  • Its last three reported values are $56.5 million in Q3 2025, $45.2 million for Q2 2025, and $40.0 million during Q1 2025.